📄 genetic and genomic medicine

Prevalence of pfkelch13 Mutations and Clinical Indicators of Artemisinin Partial Resistance in Africa: A Systematic Review and Meta-Analysis of Observational Cohorts

This systematic review and meta-analysis reveals a 6% pooled prevalence of validated *pfkelch13* mutations indicating artemisinin partial resistance in Africa, characterized by a stark geographic divide with zero prevalence in West and Central Africa but significant expansion in East African hotspots like Rwanda and Northern Uganda.

Original authors: Munyangi wa Nkola, J., Akilimali Zalagile, P., Lukuke Mbutshu, H., Kabala Munyemo, S., Ramazani Bin Eradi, I., CAMARA, A.

Published 2026-06-10

📖 7 min read🧠 Deep dive

CC BY 4.0

Original authors: Munyangi wa Nkola, J., Akilimali Zalagile, P., Lukuke Mbutshu, H., Kabala Munyemo, S., Ramazani Bin Eradi, I., CAMARA, A.

Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). ⚕️ This is an AI-generated explanation of a preprint that has not been peer-reviewed. It is not medical advice. Do not make health decisions based on this content. Read full disclaimer

The Big Picture: A "Silent Alarm" in the Malaria Fight

Imagine malaria as a relentless fire, and the world's main tool to put it out is a special fire extinguisher called Artemisinin-based Combination Therapy (ACT). For years, this extinguisher has worked perfectly, saving millions of lives.

However, this paper is a report card on a new, scary development: the fire is learning to ignore the water. The "firefighters" (the drugs) are starting to take longer to put out the flames, and in some places, the fire is actually growing back.

The authors of this paper acted like detectives. They gathered evidence from six different "crime scenes" (observational studies) across Africa involving 888 malaria cases. Their goal was to find out: Is the malaria bug evolving to resist our best drugs, and if so, where?

The Main Suspect: The "Bad Actor" Gene

The paper focuses on a specific genetic mutation in the malaria parasite called pfkelch13.

The Analogy: Think of the malaria parasite as a car. The pfkelch13 gene is the engine. Usually, the drug (Artemisinin) acts like a wrench that jams the engine, stopping the car.
The Problem: In some parasites, the engine has been modified (mutated). Now, when the wrench hits, the engine doesn't jam; it just sputters and keeps running for a while longer. This is called "partial resistance." The drug still works eventually, but it takes much longer to clear the infection.

The Investigation: A Tale of Two Continents

The detectives found a massive difference between the East and the West of Africa. It's like checking the weather: one side is sunny, and the other is in a storm.

1. The "Storm Zone" (East Africa & The Horn of Africa)

Where: Rwanda, Uganda, Ethiopia, Tanzania, and the Democratic Republic of Congo (DRC).
What they found: Here, the "bad actor" mutations are spreading fast, but with distinct local flavors.
- In Rwanda, a specific mutation (R561H) is becoming common.
- In Uganda, different mutations (like A675V and C469Y) are taking over.
- In Ethiopia, a mutation called R622I is becoming the dominant type.
- In Tanzania, the R561H mutation is found in 7-10% of cases. Crucially, genetic analysis shows this is an independent emergence from Asian strains; the Tanzanian bugs didn't copy the Asian bugs—they evolved this resistance on their own.
- In the DR Congo, a mutation called A578S was found in 1-3% of treatment-failure isolates. However, this is currently considered a "non-validated marker," meaning scientists aren't sure yet if it truly causes resistance or is just a bystander.
The Danger: In these areas, the drug is taking too long to clear the parasites. In Ethiopia, there is a dual-threat perfect storm: the R622I resistance marker is co-occurring with deletions in the hrp2/3 genes. These genes are the "ID tags" that rapid diagnostic tests (RDTs) use to find malaria. When these tags are deleted, the tests return false negatives. It’s like the criminal not only learned to run faster (resistance) but also learned to wear an invisibility cloak (evading detection), making it incredibly hard to catch and treat them.

2. The "Safe Zone" (West and Central Africa)

Where: Nigeria, Angola, Ghana, and surrounding areas.
What they found: Here, the "bad actor" mutations are at near-zero prevalence (≤1%). The malaria parasites in these areas still largely have the standard engines, and the drugs work exactly as they should.
The Nuance: While the main resistance markers are rare, they are not entirely absent. The C580Y marker has been detected sporadically at about 0.5% in Nigeria, and there is a new validated report of African-origin C580Y in Ghana.
The Angola Paradox: A distinctive finding of this review is the situation in Angola. Here, the efficacy of the standard drug combination (artemether-lumefantrine) has dropped below 90% in several provinces. However, this failure occurs without validated pfkelch13 mutations. Instead, the reduced efficacy is attributed to tolerance to the partner drug, driven by mutations in pfmdr1 and pfcrt. This discordance highlights that resistance isn't just about the artemisinin component; the partner drugs are also under pressure.

The Numbers: What the Math Says

When the authors combined all the data from the 888 cases, they calculated an average:

The Average: About 10% of the malaria parasites in Africa now carry these resistance mutations (95% CI: 4.0%-20.0%).
The Reality Check: This average is misleading. It's like saying the average temperature of a country is 70°F, but in reality, one city is 100°F (scorching) and another is 40°F (freezing).
- In the "Safe Zone," the number is near-zero (≤1%).
- In the "Storm Zone" (like parts of Uganda or Tanzania), the number jumps significantly higher.

The authors noted that the data was very "messy" (statistically speaking, they called it "high heterogeneity"). This isn't a mistake; it proves that resistance isn't spreading evenly like a fog. Instead, it's popping up in specific, isolated "hotspots" like mushrooms after rain.

The "Resistome": The Whole Toolbox

The paper also looked at other genes that might help the parasite resist other drugs (the partner drugs).

The Piperaquine Context: In Southeast Asia, a gene called pfpm2 (which acts like a shield against a specific drug) caused massive treatment failures. In Africa, scientists found this shield gene in some parasites, but it hasn't caused treatment failures yet. The manuscript clarifies that earlier reports of a significant presence of multiple pfpm2 copies were overstated. These genotypes reflect a signature of genomic plasticity rather than a functional resistance phenotype. In Mozambique, this genetic scaffold is present at a very low frequency (0.2%) without current clinical relevance in Africa.

The Hidden Factors: Why We Missed It

The paper highlights two critical factors that explain why this resistance has been so hard to detect:

The Semi-Immunity Hypothesis: In high-transmission African settings, many people have developed partial immunity to malaria. This immunity helps clear the infection quickly, masking the fact that the drug is working slower than it should. This "semi-immunity" could allow artemisinin partial resistance to circulate undetected for roughly 10 years.
The Under-5 Age Group: The clinical outcomes are heavily moderated by age. Young children (under 5 years) do not have this semi-immunity, making them the most vulnerable group where the true impact of drug resistance becomes visible.

The Conclusion: What Should We Do?

The paper concludes that Africa is at a critical turning point.

Don't Panic, But Don't Ignore: The drugs still work for most people, but the "fire" is learning to fight back in specific neighborhoods.
Stop Using a "One-Size-Fits-All" Map: You can't use the same strategy for the whole continent. What works in Nigeria (where the drug is still perfect) might fail in Uganda (where the bug is evolving) or Angola (where partner-drug tolerance is rising).
Upgrade the Surveillance: The authors suggest we need better, faster ways to catch these mutations. They propose using portable, DNA-reading devices (like a "molecular microscope") that can be used right in the village to spot the "bad actors" before they spread.

In short: The malaria parasite is evolving independently in Africa (it didn't just copy the bugs from Asia). It is creating new, resistant versions in the East, while the West remains mostly safe. The authors are sounding a warning bell: we need to watch these specific hotspots closely and change our strategies region by region before the drugs stop working entirely.

Technical Summary: Prevalence of PfKelch13 Mutations and Clinical Indicators of Artemisinin Partial Resistance in Africa

Problem Statement
Artemisinin-based combination therapies (ACTs) remain the cornerstone of malaria control in Sub-Saharan Africa, where Plasmodium falciparum causes the majority of severe cases and mortality. However, the emergence of partial artemisinin resistance, characterized by delayed parasite clearance and driven by mutations in the pfkelch13 propeller domain, poses a severe threat to elimination strategies. While resistance was first identified in the Greater Mekong Subregion, concerns have mounted regarding its independent emergence in Africa. The challenge lies in the heterogeneous nature of this resistance across the continent, complicated by high transmission intensity, host immunity, and the potential for "silent" expansion of resistant lineages that may not yet manifest as widespread clinical treatment failure. There is a critical need to synthesize longitudinal observational data to map the geographic distribution, prevalence, and clinical correlates of these molecular markers.

Methodology
This study is a systematic review and meta-analysis of observational cohort studies, conducted in strict adherence to PRISMA 2020 guidelines. The protocol was prospectively registered (PROSPERO 2026 CRD420261337147).

Search Strategy: A comprehensive search was performed across PubMed/MEDLINE, Scopus, Web of Science, and African Journals Online for studies published between January 1, 2015, and June 30, 2025.
Eligibility Criteria: Using a PICOST framework, the review included prospective observational cohorts in Africa involving human participants with confirmed P. falciparum malaria. Studies were required to include longitudinal monitoring (therapeutic efficacy studies) and pfkelch13 propeller domain genotyping.
Data Synthesis: Six core prospective cohorts met the inclusion criteria, providing a total of 888 successfully genotyped parasite isolates. The studies covered diverse geographic regions: West/Central Africa (Nigeria, Angola) and East Africa/Great Lakes (Rwanda, Uganda).
Statistical Analysis: A random-effects model was employed to calculate the pooled prevalence of validated pfkelch13 mutations, accounting for high inter-study heterogeneity. Quality assessment was conducted using the Newcastle-Ottawa Scale (NOS) and QUADAS-2 frameworks.

Key Contributions

Quantitative Synthesis: The paper provides the first meta-analytical estimate of validated pfkelch13 mutation prevalence across African observational cohorts, synthesizing data from 888 isolates.
Geographic Stratification: It delineates a profound geographic dichotomy, distinguishing between regions with established resistance hotspots and those maintaining wild-type stability.
Clinical Correlation: The study links specific molecular markers (e.g., R561H, A675V, C469Y) to clinical phenotypes, specifically delayed parasite clearance (Day 3 positivity and prolonged clearance half-life).
Resistome Context: Beyond pfkelch13, the review characterizes the broader "multidrug resistome," analyzing partner drug markers (pfmdr1, pfcrt, pfpm2) to contextualize the efficacy of current ACTs.
Methodological Rigor: By integrating NOS and QUADAS-2 assessments, the paper critically evaluates the risk of bias, particularly regarding the strategic targeting of "hotspots" versus general population representativeness.

Results

Pooled Prevalence: The meta-analysis revealed a pooled prevalence of validated pfkelch13 mutations of 10% (95% CI: 4.0%–20.0%) across the six cohorts.
Geographic Heterogeneity: The analysis identified extreme heterogeneity ( $I^2 = 96.3\%$ $I^{2} = 96.3%$ , $p < 0.001$ $p < 0.001$ ), reflecting a "patchy" emergence of resistance.
- West and Central Africa: Cohorts reported near-zero prevalence (≤1%) of validated mutations. However, the C580Y marker has been detected sporadically at about 0.5% in Nigeria, and there is a new validated report of African-origin C580Y in Ghana.
- East Africa: Significant expansion was observed. Prevalence reached 12.8% in specific sites in Rwanda and up to 25.5% in Northern Uganda.
Molecular Landscape:
- Rwanda: The R561H mutation is linked to clonal expansion and delayed clearance.
- Uganda: High frequencies of A675V, C469Y, and C580Y were documented.
- Tanzania: R561H was detected at 7–10%, representing an independent emergence from Asian strains as confirmed by flanking haplotype analysis.
- DR Congo: The non-validated marker A578S was found at 1–3% in treatment-failure isolates.
- Horn of Africa: The R622I mutation is approaching predominance in northern Ethiopia and Eritrea.
Clinical Outcomes:
- In East African hotspots, validated mutations were strongly associated with delayed parasite clearance (Day 3 positivity). However, overall therapeutic efficacy (Day 28 PCR-corrected) generally remained above the 90% WHO threshold, suggesting partner drugs are currently compensating.
- The Angola Paradox: A distinctive finding of the review is the reduced efficacy of Artemether-Lumefantrine (AL) in Angola, which fell below 90% in several provinces. This reduced efficacy occurs without validated pfkelch13 mutations and is instead attributed to pfmdr1/pfcrt partner-drug tolerance, highlighting a critical discordance between molecular markers and clinical outcomes.
- In Nigeria, high clinical efficacy and rapid clearance were maintained with wild-type profiles.
Partner Drug Markers: Earlier reports of a significant presence of multiple pfpm2 copies were overstated. These genotypes reflect a signature of genomic plasticity rather than a functional resistance phenotype. They represent a genetic scaffold present at very low frequency (0.2% in Mozambique) without current clinical relevance in Africa.

Significance and Claims
The paper claims that partial artemisinin resistance in Africa has evolved from a localized signal into a diversified continental threat characterized by independent, de novo evolutionary trajectories. The findings refute the hypothesis that African resistance is solely imported from Southeast Asia, demonstrating instead that local drug pressure and high transmission intensity are driving the emergence of distinct lineages (e.g., R561H in Rwanda and Tanzania, R622I in the Horn of Africa).

The authors assert that the 10% (95% CI: 4.0%–20.0%) pooled prevalence is a "weighted composite" that masks a critical public health crisis in specific East African hotspots where resistance is established and expanding. The study emphasizes that the current "one-size-fits-all" continental approach to malaria control is no longer viable. Instead, the paper advocates for:

Standardized, Decentralized Surveillance: Moving from reactive Therapeutic Efficacy Studies to proactive, genomic-integrated surveillance (proposing frameworks like NOMADS using portable Nanopore sequencing) to detect emerging mutations in real-time.
Regional Tailoring: Adapting ACT selection based on local resistance profiles, particularly in East African hotspots where the combination of K13 mutations and partner drug tolerance threatens first-line efficacy.
Diagnostic Integration: In the Horn of Africa, the convergence of R622I mutations with hrp2/3 deletions creates a "perfect storm" of dual threats: the co-occurrence of drug resistance markers with diagnostic gene deletions causes false-negative rapid diagnostic tests (RDTs), necessitating the dual monitoring of drug resistance and diagnostic markers.

The paper concludes that while the overall efficacy of ACTs remains high in many regions, the rapid clonal expansion of validated mutations in East Africa represents an urgent transition point for malaria control. Furthermore, the authors highlight the "semi-immunity hypothesis," suggesting that artemisinin partial resistance could circulate for roughly 10 years undetected in high-transmission African settings due to host immunity masking clinical symptoms. Additionally, the under-5 age group is identified as a critical clinical outcome moderator, as younger children may exhibit different clearance dynamics compared to older, semi-immune populations. Immediate policy shifts are required to prevent a resurgence of malaria similar to that observed in the Greater Mekong Subregion.